Navigation Links
Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013
Date:2/14/2013

es for lisdexamfetamine dimesylate(1) ("LDX")and SPD602 for Iron Overload. The effect of higher Research and Development expenditure was moderated by a lower rate of increase in Selling, General and Administrative expenditure (up 7%).

On a US GAAP basis:
Operating income in 2012 was down 14% to $949 million (2011: $1,109 million) primarily resulting from charges to impair intangible assets for RESOLOR® in the EU ($198 million) in 2012. The impairments were due to lower actual and projected performance for the product given the increasingly challenging European reimbursement environment. Operating income in 2012 was also impacted by a charge of $58 million in relation to the agreement in principle with the US Government to resolve a previously disclosed civil investigation (see page 6 for further details).
  • Non GAAP diluted earnings per American Depository Share ("ADS") increased 14% to $6.10 (2011: $5.34), due to higher Non GAAP operating income and a lower effective tax rate on Non GAAP income of 18% (2011: 22%).

    On a US GAAP basis diluted earnings per ADS decreased 13% to $3.93 (2011: $4.53) primarily due to the lower US GAAP operating income, partially offset by a lower US GAAP effective tax rate of 18% (2011: 21%).
  • Cash generation, a Non GAAP measure, grew strongly by 18% to $1,637 million (2011: $1,391 million) as higher cash receipts from gross product sales and improved cash collections for aged European receivables more than offset higher operating expenses and sales deduction payments in the year.

    Free cash flow, also a Non GAAP measure, was up 43% to $1,256 million (2011: $879 million) due to higher cash generation, lower cash tax payments and lower capital expenditure.

    On a US GAAP basis, net cash provided by operating activities was up 29% to $1,383 million (2011: $1,074 million).
  • Reflecting our strong cash generation, net cash (also a
    '/>"/>

  • SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
    2. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
    3. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
    4. Dr Steven Gillis to Join Shire Board of Directors
    5. Shire Second Quarter Product Sales Up 16%
    6. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
    7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
    8. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
    9. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
    10. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
    11. SIS Delivers Advanced Interoperability With Siemens Soarian Clinicals To Improve Efficiency, Communication
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/16/2014)... 2014   NuVascular Technologies, Inc. is ... medical devices that help millions. ... cutting-edge nanotechnology that would target serious conditions such ... The platform technology was developed over a ... in funding obtained from National Institutes of Health. ...
    (Date:10/16/2014)... Oct. 16, 2014 Ninety percent of children ... relapsed multiple times or failed to respond to standard ... cellular therapy, CTL019, developed at the Perelman School of ... today in The New England Journal ... builds on preliminary findings presented at the American Society ...
    (Date:10/16/2014)... Oct. 16, 2014   Reliant Renal Care, Inc. ... Home Choice TM Training Center at 650 ... passing all regulatory requirements without any deficiencies, our state-of- ... admitting patients. The Center focuses on the unique needs ... in the comfort of their home. The open-access facility ...
    Breaking Medicine Technology:Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6A New Choice For Dialysis Patients In Bessemer 2
    (Date:10/18/2014)... Dwight D. Im, M.D., FACOG, Director ... The National Institute of Robotic Surgery at Mercy ... world to successfully perform a minimally-invasive hysterectomy via ... Driver, developed by Intuitive Surgical, Inc. (ISRG). , ... and Drug Administration (FDA) clearance for use in ...
    (Date:10/18/2014)... Recently, BamboofloorChina.com, one of the most distinguished bamboo ... assortment of bamboo floorings to its website. For ... worldwide clients now, up to 29 percent off. , ... for sale now; most of the company’s experts have been ... than 100 different kinds of elegant bamboo products on its ...
    (Date:10/18/2014)... of Neuropsychopharmacology (ECNP) is pleased to announce that the ... Swaab, for his book, We are our Brains: From ... Media Award recognises outstanding contributions to destigmatising disorders of ... € 5,000. , The ECNP Media Award was established ... better understanding of the complexity and impact of disorders ...
    (Date:10/18/2014)... One major trend upcoming in this ... which are making efforts to encourage people to donate ... organ donation process more transparent and easy. , Analysts ... to grow at a CAGR of 16.85 percent over ... the major drivers in the market is an increase ...
    (Date:10/18/2014)... For the second time in less than a month, ... facing US businesses. On September 23rd, the warning ... employees. And now, according to this Reuters report , ... for US businesses about possible cyber espionage attacks by a ... high-value information.” , “With the constant stream of headlines ...
    Breaking Medicine News(10 mins):Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 2Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 3Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Another FBI Cyber Attack Warning for US Businesses 2Health News:Another FBI Cyber Attack Warning for US Businesses 3Health News:Another FBI Cyber Attack Warning for US Businesses 4
    ... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
    ... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
    ... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
    ... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
    ... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
    ... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
    Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
    Button shape tip, round serrated handle, dull finish, overall length 130 mm....
    ... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
    Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
    Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
    Medicine Products: